PharmacyCodes



Pramipexole en es it fr

Categoria

Pramipexole Nombres de marca, Pramipexole Analogos

Pramipexole Marca los nombres de mezcla

  • No information avaliable

    • Pramipexole Formula quimica

    C10H17N3S

    Pramipexole RX enlace

    http://www.rxlist.com/cgi/generic2/prampex.htm

    Pramipexole FDA hoja

    Pramipexole MSDS (hoja de seguridad de materiales)

    Pramipexole Sintesis de referencia

    No hay información disponible

    Pramipexole Peso molecular

    211.324 g/mol

    Pramipexole Punto de fusion

    No information avaliable

    Pramipexole H2O Solubilidad

    No hay información disponible

    Pramipexole Estado

    Solid

    Pramipexole LogP

    No information avaliable

    Pramipexole Formas de dosificacion

    Tableta

    Pramipexole Indicacion

    Para el tratamiento de los signos y síntomas de la enfermedad de Parkinson idiopática

    Pramipexole Farmacologia

    El pramipexol es un agonista de la dopamina nonergot con relativamente alta especificidad in vitro y la actividad intrínseca completa a la subfamilia de receptores de dopamina D2, la unión con mayor afinidad a la D3 que para D2 o D4 subtipos de receptores. La relevancia de la unión del receptor D3 de la enfermedad de Parkinson es desconocida. El mecanismo de acción preciso de pramipexol en el tratamiento de la enfermedad de Parkinson es desconocida, aunque se cree que estar relacionado con su capacidad de estimular los receptores de dopamina en el estriado. Esta conclusión está apoyada por estudios electrofisiológicos en animales que han demostrado que el pramipexol influye en las tasas de disparo neuronal estriatal través de la activación de los receptores de dopamina en el estriado y la sustancia negra, el sitio de las neuronas que envían proyecciones al estriado.

    Pramipexole Absorcion

    No hay información disponible

    Pramipexole Toxicidad

    No hay información disponible

    Pramipexole Informacion de Pacientes

    Patients should be instructed to take MIRAPEX only as prescribed.

    Patients should be informed that hallucinations can occur and that the elderly are at a higher risk than younger patients with Parkinson 's disease.

    Patients may develop postural (orthostatic) hypotension, with or without symptoms such as dizziness, nausea, fainting or blackouts, and sometimes, sweating. Hypotension may occur more frequently during initial therapy. Accordingly, patients should be cautioned against rising rapidly after sitting or lying down, especially if they have been doing so for prolonged periods and especially at the initiation of treatment with MIRAPEX.

    Patients should be advised that MIRAPEX may cause somnolence and that they should neither drive a car nor operate other complex machinery until they have gained sufficient experience on MIRAPEX to gauge whether or not it affects their mental and/or motor performance adversely. Because of the possible additive sedative effects, caution should also be used when patients are taking other CNS depressants in combination with MIRAPEX.

    Because the teratogenic, potential of pramipexole has not been completely established in laboratory animals, and because experience in humans is limited, patients should be advised to notify their physicians if they become pregnant or intend to become pregnant during therapy.

    Because of the possibility that pramipexole may be excreted in breast milk, patients should be advised to notify their physicians if they intend to breast-feed or are breast-feeding an infant.

    If patients develop nausea, they should be advised that taking MIRAPEX with food may reduce the occurrence of nausea.

    Pramipexole Organismos afectados

    Humanos y otros mamíferos